

1 **A population-level analysis of the protective effects of androgen deprivation therapy**
2 **against COVID-19 disease incidence and severity**

3

4 Kyung Min Lee, PhD^{1,2}, Kent Heberer, PhD^{3,4}, Anthony Gao^{1,2}, Daniel J Becker, MD, MS^{5,6},
5 Stacy Loeb, MD, MSc, PhD(hon)^{5,6}, Danil V. Makarov MD, MHS^{5,6}, Barbara Gulanski, MD^{7,8},
6 Scott L DuVall, PhD^{1,2}, Mihaela Aslan, PhD^{7,8}, Jennifer Lee, MD, PhD^{3,4}, Richard Hauger, MD,
7 PhD^{9,10} Mei-Chiung Shih, PhD^{3,4}, Julie Lynch, RN, MBA, PhD^{1,2}, Matthew Rettig, MD^{11,12}

8

9 ¹VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake
10 City, UT

11 ²Department of Internal Medicine, Division of Epidemiology, University of Utah School of
12 Medicine, Salt Lake City, UT

13 ³VA Palo Alto Healthcare System, Palo Alto, CA

14 ⁴Stanford University School of Medicine, Palo Alto, CA

15 ⁵VA New York Harbor Healthcare System, New York, NY

16 ⁶Department of Urology, Perlmutter Cancer Center, NYU Langone Health, New York, NY

17 ⁷Cooperative Studies Program Clinical Epidemiology Research Center (CSP CERC), VA
18 Connecticut Healthcare System, West Haven, CT

19 ⁸Yale School of Medicine, Yale University, New Haven, CT

20 ⁹Center of Excellence for Stress and Mental Health (CESAMH), VA San Diego Healthcare
21 System, San Diego, CA

22 ¹⁰Center for Behavior Genetics of Aging, Department of Psychiatry, University of California San
23 Diego School of Medicine, La Jolla, CA

24 ¹¹VA Greater Los Angeles Healthcare System, Los Angeles, CA

25 ¹²University of California, Los Angeles School of Medicine, Los Angeles, CA

26

27 Corresponding author: Matthew Rettig, MD (MRettig@mednet.ucla.edu)

28

29 Funding: Funding for this study was provided by the US Department of Veterans Affairs (VA),
30 Veterans Health Administration, Cooperative Studies Program, grant number 825-MS-DI-33848,
31 and used resources and facilities at the VA Informatics and Computing Infrastructure (VINCI),
32 VA HSR RES 13-457. Dr. Rettig is supported by The Prostate Cancer Foundation (PCF) David
33 Geffen Precision Oncology Center of Excellence of VAGLAHS and a Department of Veterans
34 Affairs Merit Review Award. Drs. Becker and Makarov are supported by The John and Daria
35 Barry Precision Oncology Center of Excellence of the VANYHHS, and Edward Blank and
36 Sharon Cosloy–Blank Family Foundation. Dr. Becker is supported by VA Career Development
37 Award (CDA 16-206). Dr. Makarov is a Prostate Cancer Foundation Young Investigator
38 Awardee.

39

40 The views expressed are those of the authors and do not necessarily represent the views or
41 policy of the Department of Veterans Affairs or the United States Government.

42

43 Disclosures: SL reports equity in Gilead Sciences, Inc. SLD reports research grants from the
44 following for-profit organizations outside this submitted work: Alnylam Pharmaceuticals Inc.,
45 AbbVie Inc., Astellas Pharma Inc., AstraZeneca Pharmaceuticals LP, Biodesix, Inc., Boehringer
46 Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Genentech Inc.,
47 Gilead Sciences Inc., GlaxoSmithKline PLC, Innocrin Pharmaceuticals Inc., Janssen
48 Pharmaceuticals, Inc., Kantar Health, Myriad Genetic Laboratories, Inc., Novartis International
49 AG, and Parexel International Corporation through the University of Utah or Western Institute for
50 Veteran Research.

51

52

53 **KEY POINTS**

54 **Question:** Does androgen deprivation therapy (ADT) lower incidence and severity of COVID-
55 19?

56 **Findings:** In this observational study of male Veterans treated in the Veterans Healthcare
57 System, ADT was associated with decreased likelihood of testing positive for SARS-CoV-2
58 (adjusted OR, 0.88 [95% CI, 0.81-0.95]; $p=0.001$). ADT was also associated with fewer severe
59 COVID-19 outcomes (OR 0.72 [95% CI 0.53-0.96]; $p=0.03$).

60 **Meaning:** The use of androgen deprivation therapy may be protective against SARS-CoV-2
61 infection and modulate severity of COVID-19 outcomes.

62 **ABSTRACT**

63 **Importance:** The incidence and severity of coronavirus disease 19 (COVID-19) is higher in
64 men. Sex hormones potentially offer one explanation for differences by sex.

65 **Objective:** To determine whether men exposed to androgen deprivation therapy (ADT) have
66 lower incidence and severity of COVID-19.

67 **Design:** We conducted an observational study of male Veterans treated in the Veterans Health
68 Administration from February 15th to July 15th, 2020. We developed a propensity score model
69 to predict the likelihood to undergo Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
70 CoV-2) testing. We performed multivariable logistic regression modeling adjusted with inverse
71 probability weighting to examine the relationship between ADT and COVID-19 incidence. We
72 conducted logistic regression analysis among COVID-19 patients to test the association
73 between ADT and COVID-19 severity.

74 **Setting:** The U.S. Department of Veterans Affairs

75 **Participants:** The study sample consisted of 6,250,417 male Veterans who were alive as of
76 February 15, 2020.

77 **Exposure:** Exposure to ADT was defined as having any prescription for a luteinizing hormone
78 releasing hormone analogue or an antiandrogen in the six months prior to the index date.

79 **Main Outcomes and Measures:** To assess incidence, we used a binary variable indicating any
80 positive reverse transcriptase polymerase chain reaction SARS-CoV-2 test result through July
81 15, 2020. To measure severity, we constructed a binary variable indicating whether a patient
82 was admitted to the intensive care unit, placed on mechanical ventilation, or dead in the 60 days
83 following a positive test up to July 15, 2020.

84 **Results:** We identified 246,087 patients who had been tested for SARS-CoV-2, of whom 3,057
85 were exposed to ADT, and 36,096 patients with cancer and no ADT exposure. Of these, 295
86 ADT patients and 2,427 other cancer patients had COVID-19 illness. In the primary, propensity-
87 weighted comparison of ADT patients to cancer patients not on ADT, ADT was associated with

88 decreased likelihood of testing positive for SARS-CoV-2 (adjusted OR, 0.88 [95% CI, 0.81-
89 0.95]; p=0.001). ADT was associated with fewer severe COVID-19 outcomes (OR 0.72 [95% CI
90 0.53-0.96]; p=0.03).

91 **Conclusions and Relevance:** ADT is associated with reduced incidence and severity of
92 COVID-19 amongst male Veterans. Repurposing of drugs that modulate androgen production
93 and/or action may represent viable potential treatments for COVID-19.

94 INTRODUCTION

95 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
96 coronavirus disease 2019 (COVID-19) have rapidly disseminated across the globe and caused
97 more than one million deaths.¹ The incidence and severity of COVID-19 have been related to
98 multiple factors, including age, comorbid conditions, immunosuppression, smoking, race, and
99 sex.²⁻⁴ Whereas men and women manifest a similar incidence of COVID-19, male sex is a risk
100 factor for more severe illness. The severity of COVID-19 as indicated by admission to an
101 intensive care unit (ICU), requirement for mechanical ventilation, or mortality is approximately
102 two-fold higher in men.^{5,6} This sex disparity has been observed in Asia, North America, Europe,
103 and across individual countries on each of the continents.

104 Explanations for sex differences in outcome include difference in health behaviors (e.g.
105 smoking history), incidence of comorbidities such as lung and heart disease, and biology,
106 including variations in sex hormones. Specifically, androgens including testosterone and
107 dihydrotestosterone may worsen COVID-19 severity through two non-mutually exclusive
108 physiologic effects. First, androgens are known to suppress both innate and adaptive immunity,
109 which may increase susceptibility to the SARS-CoV-2 virus and disease severity.^{7,8} Second,
110 androgens induce the expression of the two plasma membrane proteins, transmembrane
111 protease serine 2 (TMPRSS2) via an androgen response element in the promoter and
112 angiotensin converting enzyme 2 (ACE2), which are required for entry of SARS-CoV-2 into
113 epithelial cells.⁹⁻¹² Co-expression of the androgen receptor (AR), TMPRSS2, and ACE2 has
114 been observed in human pulmonary epithelial cells, alveolar type 2 pneumocytes, and nasal
115 mucosal cells which are critical sites for SARS-CoV-2 infection and disease severity.^{12,13}
116 Androgen-driven overexpression of these viral co-receptors may augment cellular entry and
117 replication of SARS-CoV-2, thereby mediating increased infection rate and COVID-19 severity
118 in men. Furthermore, men who are carriers of TMPRSS2 gene mutations, which potentiate
119 androgen-induced cellular expression of TMPRSS2, may be especially at risk for COVID-19

120 morbidity and mortality.^{14,15} TMPRSS2 gene variants has also been found to confer a two-fold
121 increase in H1N1 influenza severity supporting the hypothesis that androgen regulation of
122 TMPRSS2 may be a critical host factor for respiratory disease.¹⁶

123 These observations suggest that suppression of androgen levels may have a salutary
124 impact on COVID-19 illness. Two retrospective studies that evaluated the impact of androgen
125 deprivation therapy (ADT) on COVID-19 illness yielded conflicting results. A study from Italy
126 reported a reduced incidence of COVID-19 among patients with prostate cancer on ADT,
127 whereas a study of patients in the United States (U.S.) failed to detect a protective effect of ADT
128 on COVID-19 incidence.^{17,18} Our objective was to perform a nationwide, population-based study
129 of the relationship of ADT to the incidence and outcomes of COVID-19. Using data from the
130 U.S. Veterans Health Administration (VHA), we report the largest study to date evaluating the
131 hypothesis that androgen deprivation therapy is associated with a reduced incidence and
132 severity of COVID-19.

133

134 **METHODS**

135 Data sources

136 We used the Corporate Data Warehouse (CDW) of the VHA, a national data repository
137 that provides access to the electronic health records of all individuals who received care in the
138 VHA. In addition, we drew from the VA COVID-19 Shared Data Resource (CSDR), a newly
139 developed data domain that consists of a wide range of information related to COVID-19
140 available for all patients who received a COVID-19 laboratory test within VHA or whose positive
141 test result outside VHA was recorded in VHA clinical notes.¹⁹ This study was approved by the
142 VA Central Institutional Review Board.

143 Study sample

144 The study sample consisted of all male Veterans who were alive as of February 15,
145 2020. The earliest testing date reported in the CSDR is February 16, 2020. Therefore, we
146 considered anyone alive as of February 15, 2020 as having been eligible to be tested for SARS-
147 CoV-2. From this base sample, we assembled two sub-samples to examine incidence of
148 COVID-19 and severity of COVID-19. For incidence analysis, we derived a sample consisting of
149 patients who underwent SARS-CoV-2 testing matched to patients who did not undergo SARS-
150 CoV-2 testing on age, race, and VHA facility. Separately, we used an unmatched sample of
151 patients who tested positive for SARS-CoV-2 to investigate ADT use and COVID-19 severity.
152 The index date for the incidence analysis and the severity analysis was February 15, 2020 and
153 the date of first positive SARS-CoV-2 test result, respectively.

154 Exposure

155 Exposure to androgen deprivation therapy (ADT) was defined as having any prescription
156 for a luteinizing hormone releasing hormone analogue (LHRH) (buserelin, degarelix, goserelin,
157 historelin, leuprolide, or triptorelin) or an antiandrogen (abiraterone, apalutamide, bicalutamide,
158 cyproterone, darolutamide, enzalutamide, flutamide, ketoconazole, or nilutamide) in the six
159 months prior to the index date. A small number of patients were prescribed only antiandrogens.

160 These patients were presumed to be receiving their LHRH analogues outside the VHA because
161 it is highly unlikely to be prescribed antiandrogens as a monotherapy.

162 Endpoints

163 We investigated the relationship between ADT use and COVID-19 incidence and
164 severity. To assess incidence, we used a binary variable indicating any positive reverse
165 transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 test result through July 15,
166 2020. To measure severity, we constructed a binary variable indicating whether a patient was
167 admitted to the intensive care unit (ICU), placed on mechanical ventilation, or dead in the 60
168 days following a positive test up to July 15, 2020. Death was attributed to COVID-19 if it
169 occurred within 60 days of a positive RT-PCR test for SARS-CoV-2. The primary comparison for
170 both incidence and severity was patients with ADT exposure (ADT patients) versus patients with
171 non-prostate cancer who had no ADT exposure (non-ADT, other cancer patients). We selected
172 this as the primary comparison because the incidence and severity of COVID-19 is adversely
173 affected by a cancer diagnosis and virtually all ADT patients have high risk, recurrent, locally
174 advanced, or metastatic prostate cancer. Secondary comparisons included all patients exposed
175 to ADT versus all who were not, and patients with prostate cancer with versus without ADT
176 exposure.

177 Covariates

178 Age, race, marital status, body mass index, smoking status, the Charlson Comorbidity
179 Index categories²⁰ (excluding localized and metastatic solid tumors) in the prior two years, use
180 of selected antihypertensives—angiotensin-converting enzyme inhibitors (ACEs), angiotensin II
181 receptor blockers (ARBs), and spironolactone—in the prior six months, VHA utilization in the
182 prior year as measured by total numbers of visits and hospital days, and the number of days to
183 testing or first SARS-CoV-2 positivity were assessed at the index date. Lastly, the VHA facility of
184 COVID-19 testing was included as a fixed effect in the COVID-19 incidence models and as a
185 random effect in the COVID-19 severity models.

186 Statistical analysis

187 Multivariate logistic regression models were used to determine the association of ADT
188 exposure with SARS-CoV-2 positivity, weighted by the inverse of the predicted probabilities of
189 being tested. Due to the limited availability of SARS-CoV-2 tests, receipt of test was prioritized
190 based on a wide range of patient characteristics including demographics, comorbid conditions,
191 and severity of symptoms. Such targeted testing results in a highly selected group of patients
192 who are tested for SARS-CoV-2.²¹ To adjust for unequal probabilities of being tested, we used
193 the inverse probability weighting method, where the weight is based on the predicted
194 probabilities (propensity score) of being tested, estimated by a logistic regression model using
195 ADT exposure, selected patient covariates, and VHA facility.^{22,23} For this model, we
196 implemented a nested case-control design with incidence density sampling to match each
197 tested patient (case) to five patients who were eligible to be tested (controls) at the time of the
198 case's testing on age, race, and VHA facility.²⁴

199 Generalized linear mixed models were used to determine associations between ADT
200 exposure and severity of COVID-19 while controlling for patients' demographic and clinical
201 covariates, and the number of days from February 15 to the date of first SARS-CoV-2 positivity
202 (as fixed effects) and VHA facility (as a random effect). All male Veterans in the study sample
203 with a positive COVID-19 test were included in this analysis. We used SAS 9.2 (Cary, NC) for
204 data preparation and all statistical analyses. Two-tailed hypothesis testing was performed using
205 the significance level of 5%.

206

207 RESULTS

208 Patient characteristics

209 We identified 246,087 male patients tested for SARS-CoV-2 through July 15, 2020
210 (Table 1). Among the 246,087 tested patients, 3,057 patients were prescribed ADT and 243,030
211 were not. Compared to non-ADT patients, ADT patients were more likely to be Black (ADT 37%,
212 no ADT 24%), older (mean age 73.9 vs 62.9; $p < 0.001$), and had more comorbidities (Charlson
213 Comorbidity Index ≥ 5 in 72% of ADT patients and 28% of non-ADT patients).

214 SARS-CoV-2 positivity

215 The strategy for selecting patients to be included in the SARS-CoV-2 testing propensity
216 score model is shown in Figure 1, and the baseline characteristics of all SARS-CoV-2-tested
217 patients (cases) and the matched controls are shown in Table S1 in the Supplementary
218 Appendix. ADT patients were more likely to be tested for SARS-CoV-2 (adjusted odds ratio
219 (OR), 1.59 [95% confidence interval (CI), 1.52–1.68]; Table S2 in the Supplementary Appendix).
220 In the primary, propensity-weighted comparison of ADT versus cancer patients not on ADT,
221 ADT was associated with decreased likelihood of testing positive for SARS-CoV-2 after
222 adjusting for the covariates listed in Table 1 (OR, 0.88 [95% CI, 0.81–0.95]; $p = 0.001$; Table 2).
223 Similar results were observed in secondary comparisons of ADT patients versus all non-ADT
224 patients (OR, 0.75 [95% CI, 0.70–0.81]; $p < 0.001$; Table 2) and patients with prostate cancer on
225 ADT versus patients with prostate cancer not on ADT (OR, 0.85 [95% CI, 0.77–0.94]; $p = 0.002$;
226 Table S3 in the Supplementary Appendix).

227 COVID-19 severity

228 Our primary comparison of COVID-19 severity included 295 ADT patients with COVID-
229 19 (including 189 with prostate cancer only and 97 with prostate cancer and a second cancer
230 diagnosis), and 2,427 non-ADT, other cancer patients with COVID-19. Significant differences
231 between the two groups included age, race, smoking status, and comorbidities (Table 3).
232 Severe COVID-19 outcomes were observed in 76/295 (25%) of the ADT group and 727/2427

233 (30%) of the non-ADT group (Table 4). After controlling for clinical and demographic factors,
234 ADT was associated with fewer severe COVID-19 outcomes (OR 0.72 [95% CI 0.53–0.96];
235 $p=0.03$; Table 4). Comparisons between ADT patients versus all patients not on ADT and
236 prostate cancer patients on ADT versus prostate cancer patients not on ADT did not
237 demonstrate a statistically significant protective effect of ADT (Table 4 and Table S3 in the
238 Supplementary Appendix).
239

240 **DISCUSSION**

241 In our analysis of male U.S. Veterans tested for SARS-CoV-2, ADT use was associated
242 with a reduced incidence and severity of COVID-19 compared to Veterans with non-prostate
243 cancers who were not on ADT. The reduction in the incidence of COVID-19 was modest (OR
244 0.88) after correcting for baseline characteristics (e.g. smoking, cardiovascular disease and
245 other comorbidities, and race) and the likelihood for undergoing SARS-CoV-2 testing. A reduced
246 incidence of COVID-19 was also observed among ADT patients compared to all SARS-CoV-2-
247 tested Veterans not on ADT as well as Veterans with prostate cancer not on ADT.

248 The effects of ADT on the incidence of COVID-19 has been reported by two groups.
249 Montopoli et al. (2020) evaluated SARS-CoV-2 positive patients in the Veneto region of Italy
250 and reported that patients with a cancer diagnosis other than prostate cancer as well as patients
251 with prostate cancer not on ADT were over-represented compared to ADT patients (OR 4.86
252 [95% CI 1.88–12.56]; $p=0.001$, and OR 4.05 [95% CI 1.55–10.59]; $p=0.004$, respectively).
253 These results were based on COVID-19 incidence among all patients with cancer in the Veneto
254 region, irrespective of whether these patients had been tested for SARS-CoV-2. Whereas the
255 results from the Italian study are consistent with the protective effect of ADT on COVID-19
256 incidence in the analogous populations in the Veteran population, the magnitude of the effect
257 was far greater in the Veneto population. In contrast, Klein et al. (2020), reporting on a cohort of
258 patients from an Ohio healthcare system, observed no protective effect of ADT on incidence of
259 COVID-19 in prostate cancer patients on ADT versus prostate cancer patients not on ADT.

260 The association of ADT with the severity of COVID-19 has been reported in three
261 studies. In the Italian study, ADT was associated with a reduced likelihood of severe disease
262 (ICU admission and death), but this was premised on only four COVID-19 positive patients on
263 ADT (only 1 of whom developed severe disease), 13 COVID-19 positive patients with prostate
264 cancer not on ADT, and 89 COVID-19 positive patients with other cancers not on ADT.¹⁷ By
265 contrast, the Ohio study did not identify a protective effect of ADT on the severity of COVID-19

266 outcomes, but the authors recognized that robust statistics were not feasible due to limited
267 sample size, despite being significantly larger than the Italian cohort.¹⁸ Based on a small cohort
268 of ADT and non-ADT patients (n=22 and 36, respectively), Patel et al. (2020) reported that ADT
269 was associated with a reduced risk of hospitalization (OR 0.23 [95% CI 0.06–0.79]; p<0.02) and
270 supplemental oxygen use (OR 0.26 [95% CI 0.07–0.92]; p=0.04), and a non-statistically
271 significant trend toward a reduction in mechanical ventilation and death after correcting for age,
272 cardiac disease, and pulmonary disease.²⁵ By comparison, our study demonstrated ADT
273 exposure was associated with a reduction in COVID-19 severity (OR 0.72) compared to cancer
274 patients without ADT exposure, based on a composite endpoint of ICU admission, mechanical
275 ventilation, and death.

276 Strengths of this study include a multivariate regression analysis to account for
277 differences in baseline characteristics, which was not performed in the Italian study, as well as a
278 much larger cohort of patients in comparison to the Italian study, though still an order of
279 magnitude smaller than the current VHA cohort (e.g. n=304 and n=3,057 patients on ADT in the
280 Ohio and Veteran cohorts, respectively). Importantly, neither the Italian nor the Ohio study
281 accounted for differences in the likelihood to be tested for SARS-CoV-2 among the respective
282 populations, which can bias the COVID-19 incidence results, especially if ADT patients are
283 more likely to be tested for SARS-CoV-2. Indeed, in our Veteran population, the adjusted odds
284 ratio for SARS-CoV-2 testing was 1.59 for ADT patients, which we incorporated as a propensity
285 score in our analyses of COVID-19 incidence. In addition, our study is less subject to
286 ascertainment bias, since Veterans largely seek care within the VA healthcare system.
287 Weaknesses include the retrospective nature of the analysis and uncertainty about the
288 underlying cause for ICU admission, mechanical ventilation, and death. While we treated VHA
289 facility as a random effect in our severity analysis, the rapid change in treatment decisions and
290 ability for hospitals to handle capacity at different times in the pandemic may leave confounding
291 for patients who develop severe disease.

292 Ongoing work in VA may provide further clarify the association between ADT and
293 COVID-19 illness and determine the utility of ADT agents including LHRH analogs, androgen
294 receptor antagonists, and 5-alpha reductase inhibitors. LHRH analogs achieve castrate levels of
295 serum testosterone in virtually all patients, although the LHRH antagonist, degarelix, is the only
296 FDA-approved LHRH analog that rapidly suppresses serum testosterone concentrations. A
297 randomized, double-blind, placebo-controlled, multicenter VA trial entitled, “Hormonal
298 Intervention for the Treatment of Veterans with COVID-19 Requiring Hospitalization (HITCH)”
299 (Clinicaltrials.gov identifier NCT04397718), is prospectively testing the hypothesis that ADT with
300 the LHRH antagonist, degarelix, reduces the severity of COVID-19 illness defined by a
301 composite of ongoing hospitalization, intubation, or death within 15 days of randomization. The
302 VA Million Veteran Program MVP035 COVID-19 Disease Mechanisms study is investigating the
303 role of TMPRSS2 and other androgen-regulated genes in COVID-19 severity. Several other
304 ongoing trials in the US and abroad are investigating the effects of androgen receptor
305 antagonists (e.g. bicalutamide, enzalutamide) on COVID-19 illness.²⁶

306 There is a paucity of effective treatments for severe COVID-19. In the Solidarity trial,
307 none of remdesivir, lopinavir, hydroxychloroquine or interferon beta-1a affected mortality,
308 initiation of ventilation or duration of hospitalization, although the ACT-1 study demonstrated
309 that remdesivir reduces duration of hospitalization.^{27,28} Convalescent plasma, despite its initial
310 promise, failed to improve severity or mortality of hospitalized COVID-19 patients; likewise, IL-6
311 pathway inhibitors have not improved survival of severely ill patients.²⁹ In contrast,
312 dexamethasone is the only treatment that has been consistently shown in randomized
313 controlled trials to improve survival and risk of intubation of COVID-19 patients.^{30,31}

314

315 **CONCLUSIONS**

316 Our analysis of Veterans enrolled in the VHA suggests an association of ADT exposure
317 with reduced incidence and severity of COVID-19. Repurposing of drugs that modulate
318 androgen production and/or action may represent viable potential treatments for COVID-19.
319

320 REFERENCES

- 321 1. The World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard.
322 <https://covid19.who.int/>. Accessed December 11, 2020.
- 323 2. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities,
324 and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City
325 Area. *JAMA*. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775
- 326 3. Kopel J, Perisetti A, Roghani A, Aziz M, Gajendran M, Goyal H. Racial and Gender-
327 Based Differences in COVID-19. *Front Public Heal*. 2020;8:418.
328 doi:10.3389/fpubh.2020.00418
- 329 4. Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19.
330 Meta-analysis. *Obes Res Clin Pract*. 2020;14(4):295-300. doi:10.1016/j.orcp.2020.07.002
- 331 5. Wenham C, Smith J, Morgan R. COVID-19: the gendered impacts of the outbreak.
332 *Lancet*. 2020;395(10227):846-848. doi:10.1016/S0140-6736(20)30526-2
- 333 6. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and
334 gender on COVID-19 outcomes in Europe. *Biol Sex Differ*. 2020;11(1):29.
335 doi:10.1186/s13293-020-00304-9
- 336 7. Gubbels Bupp MR, Jorgensen TN. Androgen-Induced Immunosuppression. *Front*
337 *Immunol*. 2018;9:794. doi:10.3389/fimmu.2018.00794
- 338 8. Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of androgens on the immune
339 system. *Cell Immunol*. 2015;294(2):87-94.
340 doi:<https://doi.org/10.1016/j.cellimm.2015.02.004>
- 341 9. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
342 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A
343 Review. *JAMA*. 2020;324(8):782-793. doi:10.1001/jama.2020.12839
- 344 10. Vaduganathan M, Vardeny O, Michel T, McMurray JJ V, Pfeffer MA, Solomon SD. Renin-
345 Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J Med*.

- 346 2020;382(17):1653-1659. doi:10.1056/NEJMSr2005760
- 347 11. Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pöhlmann S. TMPRSS2 and
348 ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry
349 driven by the severe acute respiratory syndrome coronavirus spike protein. *J Virol.*
350 2014;88(2):1293-1307. doi:10.1128/JVI.02202-13
- 351 12. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on
352 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell.*
353 2020;181(2):271-280.e8. doi:<https://doi.org/10.1016/j.cell.2020.02.052>
- 354 13. Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and
355 COVID-19: Serendipity or Opportunity for Intervention? *Cancer Discov.* 2020;10(6):779-
356 782. doi:10.1158/2159-8290.CD-20-0451
- 357 14. Irham LM, Chou W-H, Calkins MJ, Adikusuma W, Hsieh S-L, Chang W-C. Genetic
358 variants that influence SARS-CoV-2 receptor TMPRSS2 expression among population
359 cohorts from multiple continents. *Biochem Biophys Res Commun.* 2020;529(2):263-269.
360 doi:<https://doi.org/10.1016/j.bbrc.2020.05.179>
- 361 15. Thunders M, Delahunt B. Gene of the month: TMPRSS2 (transmembrane serine
362 protease 2). *J Clin Pathol.* 2020;73(12):773-776. doi:10.1136/jclinpath-2020-206987
- 363 16. Cheng Z, Zhou J, To KK-W, et al. Identification of TMPRSS2 as a Susceptibility Gene for
364 Severe 2009 Pandemic A(H1N1) Influenza and A(H7N9) Influenza. *J Infect Dis.*
365 2015;212(8):1214-1221. doi:10.1093/infdis/jiv246
- 366 17. Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate
367 cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). *Ann*
368 *Oncol.* June 2020. doi:10.1016/j.annonc.2020.04.479
- 369 18. Klein EA, Li J, Milinovich A, et al. Androgen Deprivation Therapy in Men with Prostate
370 Cancer Does Not Affect Risk of Infection with SARS-CoV-2. *J Urol.* September
371 2020:101097JU00000000000000001338. doi:10.1097/JU.0000000000001338

- 372 19. Department of Veterans Affairs. COVID-19: Shared Data Resource.
373 <https://vhacdwdwhweb100.vha.med.va.gov/phenotype/index.php/COVID->
374 [19:Shared_Data_Resource](https://vhacdwdwhweb100.vha.med.va.gov/phenotype/index.php/COVID-19:Shared_Data_Resource). Accessed November 3, 2020.
- 375 20. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in
376 ICD-9-CM and ICD-10 administrative data. *Med Care*. 2005;43(11):1130-1139.
377 doi:10.1097/01.mlr.0000182534.19832.83
- 378 21. Griffith G, Morris TT, Tudball M, et al. Collider bias undermines our understanding of
379 COVID-19 disease risk and severity. *medRxiv*. 2020. doi:10.1101/2020.05.04.20090506
- 380 22. Seaman SR, White IR. Review of inverse probability weighting for dealing with missing
381 data. *Stat Methods Med Res*. 2013;22(3):278-295. doi:10.1177/0962280210395740
- 382 23. Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in
383 observational studies using weighting based on the propensity score: a primer for
384 practitioners. *BMJ-BRITISH Med J*. 2019;367. doi:10.1136/bmj.l5657
- 385 24. Biesheuvel CJ, Vergouwe Y, Oudega R, Hoes AW, Grobbee DE, Moons KG. Advantages
386 of the nested case-control design in diagnostic research. *BMC Med Res Methodol*.
387 2008;8. doi:10.1186/1471-2288-8-48
- 388 25. Patel VG, Zhong X, Liaw B, et al. Does androgen deprivation therapy protect against
389 severe complications from COVID-19? *Ann Oncol*. 2020;31(10):1419-1420.
390 doi:10.1016/j.annonc.2020.06.023
- 391 26. National Library of Medicine. ClinicalTrials.gov.
392 <https://clinicaltrials.gov/ct2/results?cond=COVID-19>.
- 393 27. Pan H, Peto R, Henao-Restrepo A-M, et al. Repurposed Antiviral Drugs for Covid-19 -
394 Interim WHO Solidarity Trial Results. *N Engl J Med*. December 2020.
395 doi:10.1056/NEJMoa2023184
- 396 28. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 -
397 Final Report. *N Engl J Med*. 2020;383(19):1813-1826. doi:10.1056/NEJMoa2007764

- 398 29. Simonovich VA, Burgos Pratz LD, Scibona P, et al. A Randomized Trial of Convalescent
399 Plasma in Covid-19 Severe Pneumonia. *N Engl J Med*. 0(0):null.
400 doi:10.1056/NEJMoa2031304
- 401 30. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.
402 Association Between Administration of Systemic Corticosteroids and Mortality Among
403 Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA*. 2020;324(13):1330-1341.
404 doi:10.1001/jama.2020.17023
- 405 31. Siemieniuk RAC, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living
406 systematic review and network meta-analysis. *BMJ*. 2020;370. doi:10.1136/bmj.m2980
407

Table 1. Baseline characteristics of patients tested for SARS-CoV-2

Characteristic	ADT ^a N=3,057		No ADT N=243,030		P-value _b	No ADT (Other cancer) N=36,096		P-value _b
Age (SD)	73.9	(9)	62.9	(15.0)	<0.001	70.2	(10)	<0.001
Race (%)					<0.001			<0.001
White, non-Hispanic	1,614	(53)	150,987	(62)		25,726	(71)	
White, Hispanic	146	(5)	14,702	(6)		1,619	(4)	
Black	1,128	(37)	57,286	(24)		6,606	(18)	
Other	35	(1)	5,174	(2)		508	(1)	
Unknown	134	(4)	14,881	(6)		1,637	(5)	
Marital Status (%)					<0.001			<0.001
Married	1,479	(48)	111,052	(46)		17,229	(48)	
Single	336	(11)	40,741	(17)		4,334	(12)	
Separated or divorced	943	(31)	76,979	(32)		11,742	(33)	
Widowed	290	(9)	12,461	(5)		2,658	(7)	
Unknown	<11 ^c	(0)	1,797	(1)		133	(0)	
BMI (SD)	29.0	(6)	29.8	(6.5)	<0.001	28.7	(6)	0.062
Smoking Status (%)					<0.001			<0.001
Current	845	(28)	79,733	(33)		11,459	(32)	
Former	1,896	(62)	129,073	(53)		21,800	(60)	
Never	316	(10)	34,224	(14)		2,837	(8)	
Charlson Comorbidity Index Score					<0.001			<0.001
0	22	(1)	68,330	(28)		2,082	(6)	
1	<11 ^c	(0)	33,924	(14)		1,847	(5)	

2	298	(10)	25,838	(11)		4,065	(11)	
3	295	(10)	26,139	(11)		4,412	(12)	
4	239	(8)	20,150	(8)		3,709	(10)	
≥ 5	2,199	(72)	68,649	(28)		19,981	(55)	
Categories (%)								
Cerebrovascular disease	473	(15)	29,599	(12)	<0.001	6,390	(18)	0.002
Congestive heart failure	672	(22)	38,749	(16)	<0.001	8,410	(23)	0.098
Chronic pulmonary disease	949	(31)	66,251	(27)	<0.001	14,534	(40)	<0.001
Dementia	507	(17)	24,562	(10)	<0.001	5,109	(14)	0.000
Diabetes without chronic complication	1,310	(43)	84,246	(35)	<0.001	15,159	(42)	0.357
Diabetes with chronic complication	918	(30)	57,977	(24)	<0.001	11,202	(31)	0.249
Hemiplegia or paraplegia	76	(2)	4,931	(2)	0.075	967	(3)	0.525
HIV/AIDS	34	(1)	2,995	(1)	0.549	555	(2)	0.064
Mild liver disease	338	(11)	29,782	(12)	0.045	6,208	(17)	<0.001
Severe liver disease	166	(5)	14,830	(6)	0.123	3,556	(10)	<0.001
Myocardial Infarction	256	(8)	15,120	(6)	<0.001	3,367	(9)	0.081
Peptic ulcer disease	60	(2)	4,473	(2)	0.618	1,128	(3)	<0.001
Peripheral vascular disease	632	(21)	36,990	(15)	<0.001	8,624	(24)	<0.001
Renal disease	1,107	(36)	53,493	(22)	<0.001	12,538	(35)	0.100
Rheumatic disease	64	(2)	4,897	(2)	0.759	988	(3)	0.035
Medications (%)								
ACE	873	(29)	57,952	(24)	<0.001	9,599	(27)	0.019
ARB	369	(12)	24,896	(10)	<0.001	4,311	(12)	0.835
Spirolactone	134	(4)	8,269	(3)	0.003	1,682	(5)	0.485
VHA utilization in the prior year								
Outpatient visits (SD)	45.8	(35.0)	32.6	(36.2)	<0.001	43.7	(38.5)	<0.001
Inpatient days (SD)	7.1	(26.7)	6.8	(28.8)	<0.001	8.9	(30.7)	0.008
Days to SARS-CoV-2 testing from 2/15/2020	103.	(31.1)	104.3	(33.1)	0.011	102.9	(32.4)	0.803

(SD)

4

)

)

)

Abbreviations: ADT, Androgen Deprivation Therapy; SD, Standard Deviation; BMI, Body Mass Index; ACE, Angiotensin-Converting Enzyme inhibitors; ARB, Angiotensin II Receptor Blockers; VHA, Veterans Health Administration; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2. Regulations prohibit displaying cell sizes of less than 11.

^a Defined as having any prescriptions for LHRH analogues or antiandrogens in the 6 months prior to 2/15/2020

^b Calculated using the Wilcoxon rank-sum test (continuous variables) or chi-square test (categorical variables)

^c Cells of value 1 to 10 are displayed as "<11" in accordance with the Rules of Behavior for Access and Use of Data from VHA Vital Status.

Table 2. Association between ADT use and SARS-CoV-2 positivity

Comparison	ADT Group	SARS-CoV-2 Positive (%)	No. Tested	Reference Group	SARS-CoV-2 Positive (%)	No. Tested	OR (95% CI)	P-value
Primary	ADT	233 (8)	3,057	Other Cancer (No ADT)	2,385 (7)	36,096	0.88 (0.81,0.95)	0.001
Secondary	ADT	233 (8)	3,057	No ADT	23,340 (10)	243,030	0.75 (0.70,0.81)	<0.001

Abbreviations: ADT, Androgen Deprivation Therapy; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2

Table 3. Baseline characteristics at first positive SARS-CoV-2 test

Characteristic	ADT ^a N=295		No ADT N=25,006		P-value ^b	No ADT (Other cancer) N=2,427		P-value ^b
Age (SD)	74.2	(10.2)	62.1	(16.4)	<0.001	71.0	(11.8)	<0.001
Race (%)	<0.001							
White, non-Hispanic	111	(38)	11,619	(46)		1,386	(57)	
White, Hispanic	13	(4)	2,406	(10)		150	(6)	
Black	152	(52)	8,580	(34)		752	(31)	
Other	<11 ^d	(0)	659	(3)		33	(1)	
Unknown	18	(6)	1,742	(7)		106	(4)	
Marital Status (%)	0.007							
Married	141	(48)	11,686	(47)		1,134	(47)	0.484
Single	43	(15)	4,460	(18)		316	(13)	
Separated or divorced	84	(28)	7,321	(29)		761	(31)	
Widowed	27	(9)	1,278	(5)		200	(8)	
Unknown	0	(0)	261	(1)		16	(1)	
BMI (SD)	28.8	(6.2)	30.4	(6.5)	<0.001	28.7	(6.5)	0.617
Smoking Status (%)	0.003							
Current	71	(24)	5,927	(24)		650	(27)	
Former	191	(65)	14,386	(58)		1,561	(64)	
Never	33	(11)	4,693	(19)		216	(9)	
Charlson Comorbidity Index Score	<0.001							
0	<11 ^d	(0)	8,004	(32)		175	(7)	<0.001
1	<11 ^d	(0)	3,868	(15)		147	(6)	
2	33	(11)	2,597	(10)		277	(11)	
3	25	(8)	2,847	(11)		301	(12)	
4	27	(9)	1,876	(8)		254	(10)	
≥ 5	208	(71)	5,814	(23)		1,273	(52)	
Categories (%)								
Cerebrovascular disease	62	(21)	2,815	(11)	<0.001	447	(18)	0.280
Congestive heart failure	77	(26)	3,314	(13)	<0.001	576	(24)	0.368
Chronic pulmonary disease	91	(31)	5,160	(21)	<0.001	843	(35)	0.184
Dementia	57	(19)	3,212	(13)	0.001	539	(22)	0.258

Diabetes without chronic complication	133	(45)	9,084	(36)	0.002	1,085	(45)	0.902
Diabetes with chronic complication	92	(31)	5,890	(24)	0.002	804	(33)	0.503
Hemiplegia or paraplegia	<11 ^d	(3)	434	(2)	0.087	75	(3)	0.971
HIV/AIDS	<11 ^d	(1)	333	(1)	0.800 ^c	43	(2)	0.605
Mild liver disease	33	(11)	2,369	(9)	0.318	370	(15)	0.064
Severe liver disease	22	(7)	1,092	(4)	0.010	201	(8)	0.626
Myocardial Infarction	24	(8)	1,088	(4)	0.002	199	(8)	0.970
Peptic ulcer disease	8	(3)	295	(1)	0.026 ^c	63	(3)	0.906
Peripheral vascular disease	62	(21)	3,040	(12)	<0.001	527	(22)	0.784
Renal disease	110	(37)	4,987	(20)	<0.001	844	(35)	0.393
Rheumatic disease	<11 ^d	(1)	375	(1)	0.335 ^c	49	(2)	0.109
Medications (%)								
ACE	90	(27)	5,134	(21)	0.005	529	(22)	0.038
ARB	39	(13)	2,489	(10)	0.063	296	(12)	0.613
Spironolactone	<11 ^d	(3)	618	(2)	0.525	89	(4)	0.592
VHA utilization in the prior year								
Outpatient visits (SD)	46.2	(42.0)	26.9	(34.7)	<0.001	42.1	(43.4)	<0.001
Inpatient days (SD)	8.2	(29.9)	7.0	(35.7)	<0.001	14.2	(50.9)	0.668
Days to SARS-CoV-2 positivity from 2/15/2020 (SD)	96.2	(38.9)	101.0	(37.7)	0.022	95.6	(37.2)	0.972

Abbreviations: ADT, Androgen Deprivation Therapy; SD, Standard Deviation; BMI, Body Mass Index; CCI, Charlson Comorbidity

Index; ACE, Angiotensin-converting enzyme inhibitors; ARB, Angiotensin II Receptor Blockers; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2. Regulations prohibit displaying cell sizes of less than 11.

^a Defined as having any prescriptions for luteinizing hormone releasing hormone analogues or antiandrogens in the 6 months prior to the date of first positive SARS-CoV-2 test.

^b Calculated using the Wilcoxon rank-sum test (continuous variables) or chi-square test (categorical variables).

^c Calculated using the two-sided Fisher's exact test.

^d Cells of value 1 to 10 are displayed as "<11" in accordance with the Rules of Behavior for Access and Use of Data from VHA Vital Status.

Table 4. Association between ADT use and COVID-19 severity

Comparison	ADT Group	Severe^a (%)	No. Positive	Reference Group	Severe* (%)	No. Positive	OR (95% CI)	P-value
Primary	ADT	76 (26)	295	Other cancer, No ADT	727 (30)	2,427	0.72 (0.53,0.96)	0.025
Secondary	ADT	76 (26)	295	No ADT	4,363 (17)	25,006	0.88 (0.66,1.17)	0.372

Abbreviations: ADT, Androgen Deprivation Therapy; COVID-19, Coronavirus Disease 2019

^a Severe is defined as ICU admission, mechanical ventilation, or death in the 60 days following SARS-CoV-2 positivity




Figure 1. Consort diagram for the selection of patients for the model for the propensity to be tested for SARS-CoV-2. Curved arrows indicate excluded patients

